Skip to content
The Kids Research Institute Australia logo
Donate

Search

The NICE GUT Trial

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

The ORVAC Trial - A phase IV, double-blind, randomised, placebo-controlled clinical trial to optimise the delivery of RV1 rotavirus vaccine to Northern Territory Aboriginal infants

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

Whither pertussis?

This article discusses the rising prevalence of pertussis disease in countries which have switched to acellular vaccines.

Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015

This paper reports the results from the safety surveillance of influenza vaccines in children in Australia, in 2015.

Characterization of G2P[4] rotavirus strains causing outbreaks of gastroenteritis in the Northern Territory, Australia, in 1999, 2004 and 2009

Outbreaks of rotavirus diarrhea cause a large disease burden in the Alice Springs region of the Northern Territory, Australia.

Management of invasive group A streptococcal infections

Invasive group A streptococcal disease in children includes deep soft tissue infection, bacteraemia, bacteraemic pneumonia, meningitis and osteomyelitis

Parental Tdap boosters and infant pertussis: a case-control study

Case households had fewer immunized mothers (22% vs 32%) or fathers (20% vs 31%) but were more likely to include additional and older children. After...

Assessing the effect of meningitis prevention and treatment.

In high-income countries serious bacterial infections such as meningitis are uncommon, but their severity has led to prompt adoption of vaccines for...

Nitazoxanide for the treatment of infectious diarrhoea in the Northern Territory, Australia 2007-2012

This paper examines the use of a new antibiotic to treat diarrhoea cause by Cryptosporidium infection in Australian Indigenous children.

Duration of protection after first dose of acellular pertussis vaccine in infants

Without a booster dose, the effectiveness of 3 doses waned more rapidly from 2 to 4 years of age than previously documented for children >6 years of age who...